October 12, 2017 10:53 AM EDT
R&D

NIH al­lies with 11 top can­cer bio­phar­ma play­ers in $215M dri­ve to ex­plore bio­mark­ers, speed R&D

John Carroll

Editor & Founder

A who’s who of can­cer drug R&D com­pa­nies have band­ed to­geth­er to help fund a $215 mil­lion dri­ve at the NIH to ex­plore rel­e­vant …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Ex-Kite lead­ers step in at Kyver­na as CEO ex­its af­ter land­ing year's sec­ond-biggest IPO

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

BioN­Tech rolls out Phase 2 lung can­cer da­ta as VEGF bis­pecifics take cen­ter stage

Im­mat­ics los­es Bris­tol My­er­s' sup­port on Phase 1 bis­pe­cif­ic T cell en­gager

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times